We undertooka clinical evaluation of PG-501, 6, 6, 9-trimethyl-9-azabicyclo [3, 3, 1] non-3 β-yl α, α-di (2-thienyl) glycolate hydrochloride, in fourteen patients with Parkinsonism, two with headtremor and one with postural tremor, particularly to observe its effect on tremor.
Improvement in tremor was observed in 78% of the patients with Parkinsonism and in 100% of the others. The other symptoms of Parkinsonism, rigidity and akinesia, were improved in 3 of the fourteen patients, but 8 patients experienced improvement in tremor only.
Side effects encountered in certain cases consisted of nausea, anorexia, vertigo and headache, but they disappeared upon discontinuance of administration of PG-501.
We conclude that PG-501 is effective in improving tremor caused by Parkinsonism and other diseases.

View full abstract

Many investigators have recently reported marked beneficial effects of L-DOPA in the treatment of Parkinsonism.
This author has already reported clinical ex periences with L-DOPA in the treatment of 145 cases of Parkinsonism at St. Barnabas Hospital in N. Y. C., published in the Japanese Journal of Brain and Nerve on December 1970.
In this report, following results were stressed. Namely, 80.7% of the patients showed some improvement of symptoms and especially such symptoms as rigidity, bradykinesia, difficulty of speech and ambulation showed moderate or significant improvement, while tremor was unable to get significant relief.
This time, the author is reporting clinical experiences with APD-512 (L-DOPA) in the treatment of 14 cases of Parkinsonism, treated at Sapporo District Hospital, Ground Self Defense Force, Japan.
The results are summarized as follows: —
1. APD-512 was given orally in every case.
Initial daily doses started at 500 mg and were increased gradually every couple of days.
2. Initial effective daily doses were proved to be 1.5 or 2.0 gm and an average daily maintenance dosage between 2.0 gm and 4.0 gm was sufflcient.
3. All 14 cases were responsive to the drug, with apparent improvement of Parkinsonian symptoms.
4. Side effects were almost the same as experienced in previous cases, including nausea, vomiting, anorexia, psychic reaction, etc. However, the severity of these complaints was lighter in Japanese cases.
5. Marked improvement was noted in such symptoms as rigidity, akinesia, gait and balance and A. D. L., while there was a minimal improvement in tremor.
6. The relationship between the severity of the disease and the beneficial effect of APD-512 was very hard to assess in this small series. However, it appears that far advanced cases of the disease show very little marked improvement from the drug so far.
These results are almost coincident with other investigators' reports that APD-512 (L-DOPA) is the most useful antiparkinsonian drug ever used.

View full abstract